Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001781002-20-000005
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-06 18:10:27
Reporting Period:
2020-02-04
Accepted Time:
2020-02-06 18:10:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1082038 Durect Corp DRRX Pharmaceutical Preparations (2834) 943297098
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1781002 Bleichroeder Lp 1345 Avenue Of The Americas
47Th Floor
New York NY 10105
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-04 77,500 $1.70 26,554,046 No 4 P Indirect See footnote
Common Stock Acquisiton 2020-02-05 74,998 $1.69 26,629,044 No 4 P Indirect See footnote
Common Stock Acquisiton 2020-02-06 75,000 $1.65 26,704,044 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The reported price in Column 4 is a weighted average price. These shares were bought in multiple transactions. On 02/04/2020, prices ranged from $1.68 to $1.71 per share, inclusive. On 02/05/2020, prices ranged from $1.675 to $1.70 per share, inclusive. On 02/06/2020, prices ranged from $1.605 to $1.69 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The shares of Common Stock reported herein are indirectly beneficially owned by Bleichroeder, LP (Bleichroeder), a Delaware limited partnership, an investment adviser registered under the Investment Advisers Act of 1940. Bleichroeder is the registered investment adviser to Biotechnology Master Fund, Ltd. as well as to 21 April Fund, LP and 21 April Fund, Ltd. (collectively, the "Funds"). The shares of Common Stock reported herein are directly held by the Funds and other managedaccounts. Bleichroeder disclaims beneficial ownership of the shares of Common Stock held directly by the Funds and other managed accounts except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that Bleichroeder is the beneficial owner of any such securities.